PRNewsWire
10 Jul 2026, 00:57 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Ionis Pharmaceuticals' Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint of reducing combined cardiovascular death and recurrent events. — The failure of a Phase-3 trial for a major program typically results in a significant loss of future revenue potential and a sharp decline in valuation.
-0.90The law firm Levi & Korsinsky has launched an investigation into whether Ionis made materially false or misleading statements regarding the CARDIO-TTRansform program. — Securities litigation increases legal risk and can lead to costly settlements, though it is a secondary effect to the trial failure itself.
-0.30Which stocks this story touches
The company's Phase-3 CARDIO-TTRansform trial failed its primary endpoint, leading to a 20% stock price drop and a securities fraud investigation.
Continue reading
6 related stories
Top 3 movers · tap to explore
AstraZeneca was the partner in the failed Phase-3 CARDIO-TTRansform trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
